Metformin and reduced risk of cancer in diabetic patients

By J. Evans, L. Donnelly, A. Emslie-Smith, D. Alessi, A. Morris. British medical journal, 2005

2,407 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology, Surgery

View Paper: https://www.semanticscholar.org/paper/dcf3a0b76657e7e6f7ca73928cdfad3faa02da25

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

In Molecular Biology

In Surgery

Citations in the corpus

Targeting Metabolism for Cancer Therapy (2017, background): “Furthermore, retrospective clinical studies have found that metformin use is associated with improved cancer outcomes, reductions in cancer incidence, and decreased cancer mortality (Evans et al., 2005; Franciosi et al., 2013; Gandini et al., 2014; Lee et al., 2012; Noto et al., 2012).”
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level (2008, background): “Recent data suggest that metformin could protect from cancer (Schneider et al., 2001; Evans et al., 2005) and inhibit breast and glial cancer cell proliferation in vitro (Zakikhani et al.”
Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. (2007, background): “Recent population-based studies of type 2 diabetes patients have reported that metformin treatment is associated with a reduced cancer incidence and mortality (19, 20).”
Rapamycin passes the torch: a new generation of mTOR inhibitors (2011, background): “Metformin is a widely prescribed anti-diabetic drug, and epidemiological studies have repeatedly confirmed a lower incidence of a broad range of cancers among diabetic patients taking metformi”
AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. (2011, background): “It was found that diabetics that had been treated with metformin had a significantly lower incidence of cancer than those on other treatments (Evans et al. 2005).”
Anti-Inflammatory Effects of Metformin Irrespective of Diabetes Status (2016, positive): “652 Metformin is the first-line drug in type 2 diabetes mellitus because compared with other type 2 diabetes mellitus treatments, in both clinical trials and in observational studies, metformin monotherapy is associated with fewer adverse cardiovascular events,(1,2) and in some studies, a reduced ri”
Insulin and insulin-like growth factor signalling in neoplasia (2008, background): “— might be associated with reduced cancer incidence and mortalit”
AMPK is a negative regulator of the Warburg Effect and suppresses tumor growth in vivo (2012, methodology): “Our data provide amechanistic rationale in support of the use of AMPK agonists such as metformin for cancer therapy (Buzzai et al., 2007; Evans et al., 2005), as the efficacy of these agents against tumor growth may lie in their ability to engage AMPK-dependent metabolic checkpoints to restrict…”
Metformin: historical overview (2017, background): “Reduced cancer risk was tentatively indicated in the UKPDS and has subsequently been identified in large database analyses, suggesting that metformin might protect against certain cancers in individuals with type 2 diabetes, notably in the bowel where drug exposure is high, and this has opened a who”
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes (2009, methodology): “Concomitant metformin was introduced as a covariate into the Cox models for the insulin-regimen subgroup since it has been reported to be associated with a reduced cancer risk [5, 6].”
AMPK in Health and Disease. (2009, methodology): “The mammalian AMPK domain limits were established experimentally by partial proteolysis (395), and a stable rat 1(68-163) fragment was expressed and crystallized in the presence of -cyclodextrin (an 1-4 linked heptaglucan), as had previously been performed for other starch binding domain structural ”
Targeting cancer metabolism: a therapeutic window opens (2011, background): “As a result, antidiabetic drugs are being explored for antitumour activity, and retrospective clinical studies have shown a reduction in cancer-related mortality in patients with diabetes who are taking metformi”